Clinical trials
Diffuse Cutaneous Systemic Sclerosis clinical trials
Below are recruiting diffuse cutaneous systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse cutaneous systemic sclerosis?
- Yes. Clin2 currently lists 35 recruiting diffuse cutaneous systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse cutaneous systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse cutaneous systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.